CN104822386B - 从东北婆婆纳中分离的含有大量活性成分的纯化提取物、其制备以及包含该提取物作为活性成分用于预防或治疗炎症、过敏和哮喘的组合物 - Google Patents
从东北婆婆纳中分离的含有大量活性成分的纯化提取物、其制备以及包含该提取物作为活性成分用于预防或治疗炎症、过敏和哮喘的组合物 Download PDFInfo
- Publication number
- CN104822386B CN104822386B CN201380062681.8A CN201380062681A CN104822386B CN 104822386 B CN104822386 B CN 104822386B CN 201380062681 A CN201380062681 A CN 201380062681A CN 104822386 B CN104822386 B CN 104822386B
- Authority
- CN
- China
- Prior art keywords
- extract
- butanol
- asthma
- herba veronicae
- fractional distillation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 179
- 208000006673 asthma Diseases 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title abstract description 57
- 239000000203 mixture Substances 0.000 title description 54
- 206010020751 Hypersensitivity Diseases 0.000 title description 9
- 206010061218 Inflammation Diseases 0.000 title description 9
- 208000026935 allergic disease Diseases 0.000 title description 9
- 230000007815 allergy Effects 0.000 title description 9
- 230000004054 inflammatory process Effects 0.000 title description 9
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 claims abstract description 65
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 claims abstract description 65
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 30
- 206010002198 Anaphylactic reaction Diseases 0.000 claims abstract description 27
- 208000003455 anaphylaxis Diseases 0.000 claims abstract description 27
- 230000036783 anaphylactic response Effects 0.000 claims abstract description 26
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 17
- AKNILCMFRRDTEY-NUGKWEEESA-N [(1as,1bs,2s,5ar,6s,6as)-1a-(hydroxymethyl)-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl] 4-hydroxy-3-methoxybenzoate Chemical compound C1=C(O)C(OC)=CC(C(=O)O[C@H]2[C@H]3[C@H]([C@@H](OC=C3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@]3(CO)O[C@H]32)=C1 AKNILCMFRRDTEY-NUGKWEEESA-N 0.000 claims description 106
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 98
- AKNILCMFRRDTEY-UHFFFAOYSA-N picroside II Natural products C1=C(O)C(OC)=CC(C(=O)OC2C3C(C(OC=C3)OC3C(C(O)C(O)C(CO)O3)O)C3(CO)OC32)=C1 AKNILCMFRRDTEY-UHFFFAOYSA-N 0.000 claims description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 64
- UXSACQOOWZMGSE-RWORTQBESA-N [(1as,1bs,2s,5ar,6s,6as)-1a-(hydroxymethyl)-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl] 4-hydroxybenzoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](OC(=O)C=3C=CC(O)=CC=3)[C@@H]2C=CO1 UXSACQOOWZMGSE-RWORTQBESA-N 0.000 claims description 46
- 238000004508 fractional distillation Methods 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- JPLOCWOFCUFHBG-UHFFFAOYSA-N 6-O-Veratroyl-catalpol Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C(C=COC2OC3C(C(O)C(O)C(CO)O3)O)C2C2(CO)OC21 JPLOCWOFCUFHBG-UHFFFAOYSA-N 0.000 claims description 37
- JPLOCWOFCUFHBG-PIAIVMLOSA-N [(1as,1bs,2s,5ar,6s,6as)-1a-(hydroxymethyl)-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl] 3,4-dimethoxybenzoate Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@H]1[C@H](C=CO[C@H]2O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]2[C@@]2(CO)O[C@H]21 JPLOCWOFCUFHBG-PIAIVMLOSA-N 0.000 claims description 37
- ZSVGHBSAINKGKE-UHFFFAOYSA-N pakiside A Natural products COc1ccc(cc1OC)C(=O)OCC23OC2C(O)C4C=COC(OC5OC(CO)C(O)C(O)C5O)C34 ZSVGHBSAINKGKE-UHFFFAOYSA-N 0.000 claims description 37
- AKNILCMFRRDTEY-UTPSRAKLSA-N COc1cc(ccc1O)C(=O)O[C@@H]1[C@@H]2O[C@]2(CO)C2C1C=CO[C@H]2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound COc1cc(ccc1O)C(=O)O[C@@H]1[C@@H]2O[C@]2(CO)C2C1C=CO[C@H]2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AKNILCMFRRDTEY-UTPSRAKLSA-N 0.000 claims description 35
- JANLDILJJLTVDB-UHFFFAOYSA-N amphicoside Natural products C1=C(O)C(OC)=CC(C(=O)OCC23C(O2)C(O)C2C3C(OC3C(C(O)C(O)C(CO)O3)O)OC=C2)=C1 JANLDILJJLTVDB-UHFFFAOYSA-N 0.000 claims description 35
- KDSWDGKIENPKLB-QJDQKFITSA-N verbascoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)CCC=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O KDSWDGKIENPKLB-QJDQKFITSA-N 0.000 claims description 35
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims description 35
- 235000013305 food Nutrition 0.000 claims description 31
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 claims description 21
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 claims description 21
- 238000003809 water extraction Methods 0.000 claims description 13
- 238000010992 reflux Methods 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims description 9
- 208000010668 atopic eczema Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 206010011224 Cough Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 206010012442 Dermatitis contact Diseases 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 4
- 208000010247 contact dermatitis Diseases 0.000 claims description 4
- 239000000428 dust Substances 0.000 claims description 4
- 201000003068 rheumatic fever Diseases 0.000 claims description 4
- 238000003915 air pollution Methods 0.000 claims description 3
- 235000019504 cigarettes Nutrition 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 239000004576 sand Substances 0.000 claims description 3
- 239000000779 smoke Substances 0.000 claims description 3
- 208000010201 Exanthema Diseases 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 49
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 abstract description 19
- 206010070834 Sensitisation Diseases 0.000 abstract description 16
- 230000008313 sensitization Effects 0.000 abstract description 16
- 235000013402 health food Nutrition 0.000 abstract description 15
- 230000005764 inhibitory process Effects 0.000 abstract description 14
- 230000036428 airway hyperreactivity Effects 0.000 abstract description 13
- 210000000222 eosinocyte Anatomy 0.000 abstract description 12
- 230000003266 anti-allergic effect Effects 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 11
- 210000002175 goblet cell Anatomy 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 10
- 230000001629 suppression Effects 0.000 abstract description 10
- 230000001088 anti-asthma Effects 0.000 abstract description 9
- 238000010172 mouse model Methods 0.000 abstract description 9
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 6
- 102000018358 immunoglobulin Human genes 0.000 abstract description 6
- 102000019034 Chemokines Human genes 0.000 abstract description 5
- 108010012236 Chemokines Proteins 0.000 abstract description 5
- 210000002381 plasma Anatomy 0.000 abstract description 5
- 206010020718 hyperplasia Diseases 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 41
- 235000019441 ethanol Nutrition 0.000 description 26
- 239000000047 product Substances 0.000 description 24
- 230000008569 process Effects 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 19
- 210000004969 inflammatory cell Anatomy 0.000 description 18
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 17
- 229960005127 montelukast Drugs 0.000 description 17
- 238000004810 partition chromatography Methods 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 235000013361 beverage Nutrition 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 12
- 108090000695 Cytokines Proteins 0.000 description 12
- 239000000287 crude extract Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 241001597008 Nomeidae Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- -1 oxalyl Catalpol Chemical compound 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102000003777 Interleukin-1 beta Human genes 0.000 description 8
- 108090000193 Interleukin-1 beta Proteins 0.000 description 8
- 108090000176 Interleukin-13 Proteins 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 108010002616 Interleukin-5 Proteins 0.000 description 8
- 239000000654 additive Substances 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000007717 exclusion Effects 0.000 description 7
- 229930182470 glycoside Natural products 0.000 description 7
- 150000002338 glycosides Chemical class 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 235000012149 noodles Nutrition 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 229920001429 chelating resin Polymers 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000004255 ion exchange chromatography Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 6
- 229960002329 methacholine Drugs 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000012507 Sephadex™ Substances 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 230000002052 anaphylactic effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 244000262907 Veronica longifolia Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 210000003123 bronchiole Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 235000015067 sauces Nutrition 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 3
- 240000004528 Catalpa ovata Species 0.000 description 3
- 235000010005 Catalpa ovata Nutrition 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000024711 extrinsic asthma Diseases 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- SRWGFCAEAIUWSK-UHFFFAOYSA-N verminoside Natural products CC12OC1C(OC(=O)C=Cc3ccc(O)c(O)c3)C4C=COC(OC5OC(CO)C(O)C(O)C5O)C24 SRWGFCAEAIUWSK-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000001384 fluorosyl group Chemical group O=F[*] 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 201000010659 intrinsic asthma Diseases 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- LRHHPZILMPIMIY-KZOWKLRMSA-N minecoside Natural products COc1ccc(C=CC(=O)O[C@@H]2[C@@H]3O[C@]3(CO)[C@@H]3[C@H]2C=CO[C@H]3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1O LRHHPZILMPIMIY-KZOWKLRMSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- 229960002635 potassium citrate Drugs 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- 235000011082 potassium citrates Nutrition 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000238659 Blatta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000238710 Dermatophagoides Species 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001482592 Oreamnos americanus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 241000238661 Periplaneta Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 206010067130 Spastic diplegia Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 235000004775 Veronica rotunda var subintegra Nutrition 0.000 description 1
- 244000288237 Veronica rotunda var. subintegra Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JADZPWILSJVZBO-UHFFFAOYSA-N benzoylcatalpol Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(COC(=O)C=4C=CC=CC=4)OC3C(O)C2C=CO1 JADZPWILSJVZBO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000012174 carbonated soft drink Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 235000013766 direct food additive Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000010610 frozen noodles Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 235000019531 indirect food additive Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- DSVKJARKMOAAKJ-UHFFFAOYSA-N isovanillyl catalpol Natural products C1=C(O)C(OC)=CC=C1C(=O)OC1C(C=COC2OC3C(C(O)C(O)C(CO)O3)O)C2C2(CO)OC21 DSVKJARKMOAAKJ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- LRHHPZILMPIMIY-GGKKSNITSA-N minecoside Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C(=O)O[C@H]1[C@H](C=CO[C@H]2O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]2[C@@]2(CO)O[C@H]21 LRHHPZILMPIMIY-GGKKSNITSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011889 obduction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- MZQXNUBTVLKMLP-QOEJBJAYSA-N verminoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](OC(=O)\C=C\C=3C=C(O)C(O)=CC=3)[C@@H]2C=CO1 MZQXNUBTVLKMLP-QOEJBJAYSA-N 0.000 description 1
- DBUOUVZMYWYRRI-YWEKDMGLSA-N verproside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](OC(=O)C=3C=C(O)C(O)=CC=3)[C@@H]2C=CO1 DBUOUVZMYWYRRI-YWEKDMGLSA-N 0.000 description 1
- BVBJSLWZAPVJKX-UHFFFAOYSA-N verproside Natural products OCC1OC(OC2OC=CC3C(O)C4OC4(COC(=O)c5ccc(O)c(O)c5)C23)C(O)C(O)C1O BVBJSLWZAPVJKX-UHFFFAOYSA-N 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pediatric Medicine (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
Abstract
本发明涉及用于从东北婆婆纳的提取物制备含有比通过在现有技术中公开的传统制备方法制备的提取物更大量的活性成分(例如梓醇衍生物)的纯化提取物的本发明的新的工业化方法,以及含有该纯化提取物的用于治疗和预防炎性、过敏性或哮喘性疾病的治疗剂或功能性健康食品。通过在OVA致敏/激发小鼠模型中的各种体内试验(例如对于嗜酸性粒细胞繁殖、血浆和支气管肺泡液中免疫球蛋白和炎症趋化因子的释放的抑制试验以及气道高反应性和杯形细胞增生的抑制),所述纯化提取物表现出比通过在现有技术中公开的传统制备方法制备的提取物更有效的抗炎、抗过敏和抗哮喘活性。
Description
技术领域
本发明涉及一种从东北婆婆纳(Pseudolysimachion rotundum var.subintegrum)中分离的含有大量活性成分的纯化提取物、其制备以及包含该提取物作为活性成分用于预防或治疗炎症、过敏和哮喘的组合物。
背景技术
通常,炎症反应是在组织或细胞受到任何侵袭引起组织或细胞中的某些器质性变化的情况下,与水肿、疼痛等有关的人体的正常反应。最近,各种细胞因子已被发现与炎性疾病有关。
过敏反应可以根据反应类型分为四类,即,I型、II型、III型和IV型;或者根据从过敏原引起再致敏时间至反应发作时间的周期的类型分为两类,即,速发型过敏反应(例如I型、II型或III型)和缓发型过敏反应(例如IV型)。
其中,I型过敏与IgE抗体有关且被称为过敏反应型过敏,引起支气管哮喘、特应性疾病(例如皮炎或胃肠炎等)、过敏性鼻炎(例如花粉症)、过敏性结膜炎、食物过敏等。
哮喘被视为一种气道的复杂综合征,其特征在于各种临床症状,例如,咳嗽、由气流阻塞造成的呼吸困难、急性或慢性气道炎症、气道高反应性(AHR)和结构性重塑,并且可以是可逆或不可逆恢复的。大多数哮喘是过敏性疾病,其特征是慢性气道炎症和支气管高反应性(Minoguchi K和Adachi M.,哮喘病理生理学(Pathophysiology of asthma),在:Cherniack NS,Altose MD,Homma I.编辑,呼吸系统疾病患者的康复(Rehabilitation ofthe patient with respiratory disease),纽约:McGraw-Hill,1999年,第97-104页)。
哮喘可分为两种类型,即,外源性哮喘和内源性哮喘。外源性哮喘是由接触抗原引起的,在针对抗原的皮肤试验或支气管激发试验中显示阳性反应。通常发生的年龄趋向年轻化。它主要是由屋尘螨表皮螨属(House Dust Mite Dermatophagoides)和花粉、动物上皮、真菌等引起。内源性哮喘是由上呼吸道感染、运动、情绪不稳定、气候或湿度变化引起的,其常见于成人患者。此外,由于在血清中IgE的增加,可以通过皮肤试验检测外源性哮喘的IgE抗原。
关于病理生理学,哮喘通过T-helper2(Th2)-细胞驱动的慢性炎症识别,并且来自气道中的免疫细胞和结构细胞的各种炎症介质(例如细胞因子、趋化因子、信号分子、粘附分子和生长因子)涉及哮喘的各个阶段(Elias JA等人,J Clin Invest.,111,第291-7页,2003)。患有哮喘的患者支气管中的活化的炎性细胞(例如嗜酸性粒细胞、肥大细胞、肺泡巨噬细胞等),释放各种炎症介质(例如半胱氨酸白三烯、前列腺素等),并且涉及有力的支气管收缩(Maggi E.,Immunotechnology 3,第233-244页,1998;Pawankar R.Curr.Opin.Allergy Clin.Immunol.,1,第3-6页,2001;Barnes PJ等人,Phamacol.Rev.50,第515-596页,1998)。
因此,由于涉及炎性细胞活化的各种细胞因子(例如IL-4、IL-5、IL-13等)和IgE的再现,以及从炎性细胞中释放的半胱氨酸白三烯的再现是炎症、过敏性反应和哮喘的主要成因,至今已经进行了许多研究以开发抑制上述物质再现的抑制剂。
本发明人致力于开发源自具有安全性和有效性的天然资源(例如植物、动物等)的具有有效的抑制炎性细胞增殖的活性的有效的治疗剂,最终发现,长叶婆婆纳(Pseudolysimachion longifolium)的提取物显示出有效的抗炎、抗过敏和抗哮喘活性(韩国专利第10-860080号),并且从中分离的各种化合物(例如,毛蕊花甙(verproside)(6-O-3,4-二羟基苯甲酰基梓醇(6-O-3,4-dihydroxybenzoyl catalpol))、胡黄连苷II(picrosideⅡ)(6-O-4-羟基-3-甲氧基苯甲酰基梓醇(6-O-4-hydroxy-3-methoxybenzoyl catalpol))、梓醇6-咖啡酸酯(verminoside)(6-O-3,4-二羟基肉桂酰基梓醇(6-O-3,4-Dihydroxy cinnamoylcatalpol))、6-O-藜芦酰基梓醇(6-O-veratroyl catalpol)(6-O-3,4-二甲氧基苯甲酰基梓醇(6-O-3,4-Dimethoxy benzoyl catalpol))、米内苷(minecoside)(6-O-3-羟基-4-甲氧基肉桂酰基梓醇(6-O-3-hydroxy-4-methoxycinnamoyl catalpol))、梓醇等)也显示出有效的抗炎、抗过敏和抗哮喘活性(韩国专利公开第10-2006-125499号)。
然而,由于长叶婆婆纳的提取物含有非常少的活性成分(例如梓醇(catalopol)衍生物),通过使用该植物提取物进行大量生产和工业化存在困难。
东北婆婆纳是一种分布在韩国、中国、日本、萨哈林岛(Ostrov Sakhalin)和俄罗斯的多年生草本植物。
基于韩国专利第10-860080号中公开的对于长叶婆婆纳的提取物的抗炎、抗过敏和抗哮喘活性的先前研究,本发明人尝试开发从东北婆婆纳的提取物分离的显示抗炎、抗过敏和抗哮喘活性的更有效且更大量的成分的更有效率的制备方法。
然而,尚未有报道或公开有关用于制备从东北婆婆纳的提取物分离的比在上述引用的文献中更有效且更大量的显示抗炎、抗过敏和抗哮喘活性的成分的有效方法,其公开的内容在此通过引用并入本文中。
因此,本发明人发现了用于从东北婆婆纳的提取物制备含有更大量的活性成分(例如梓醇衍生物)的纯化提取物的新的工业化方法,并且通过在OVA致敏/激发小鼠模型中的各种体内试验,例如对于嗜酸性粒细胞繁殖、血浆和支气管肺泡液中免疫球蛋白和炎症趋化因子的释放的抑制试验以及气道高反应性和杯形细胞增生的抑制),所述纯化提取物表现出比通过在现有技术中公开的传统制备方法制备的提取物更有效的抗炎、抗过敏和抗哮喘活性。
发明内容
【技术问题】
本发明提供了一种用于从东北婆婆纳制备含有大量的活性成分(例如梓醇衍生物)的纯化提取物的新方法以及由此制备的提取物。
本发明还提供了一种药物组合物和健康食品,其含有对治疗和预防炎性、过敏性或哮喘性疾病而言有效量的从东北婆婆纳制备的包含大量的活性成分(例如梓醇衍生物)的纯化提取物作为活性成分。
本发明还提供了一种显示抗炎、抗过敏和抗哮喘活性的从东北婆婆纳制备的含有大量的活性成分(例如梓醇衍生物)的纯化提取物的用途。
本发明还提供了在哺乳动物中治疗或预防炎性、过敏性或哮喘性疾病的方法,包括:给所述哺乳动物施用有效量的从东北婆婆纳制备的含有大量活性成分(例如梓醇衍生物)的纯化提取物及其药学可接受的载体。
【技术方案】
因此,本发明的一个目的是提供从东北婆婆纳的提取物制备的含有大量的梓醇衍生物的新的纯化提取物。
本文公开的术语“梓醇衍生物”包括毛蕊花甙、梓苷、胡黄连苷Ⅱ、异香草酰梓醇(isovanilloyl catalpol)和6-O-藜芦酰梓醇等。
本文公开的术语“东北婆婆纳”包括培养的或天然生长的植物和市售的植物,但不意欲限制到上述范围内。
本文公开的术语“新的纯化提取物”包含:(a)用丁醇分馏的纯化提取物(下文中称为“ATC1”)和(b)二级分馏的纯化提取物(下文中称为“ATC2”)。
具体地,术语“用丁醇分馏的纯化提取物(ATC1)”的特征在于,基于东北婆婆纳的总提取物的重量(100%),含有15-50%(w/w)毛蕊花甙、0.3-10%(w/w)藜芦酸、0.5-10%(w/w)梓苷、0.3-10%(w/w)胡黄连苷II、0.3-10%(w/w)异香草酰梓醇和0.3-10%(w/w)6-O-藜芦酰梓醇;优选地,基于东北婆婆纳的总提取物的重量(100%),含有20-25%(w/w)毛蕊花甙、0.5-5%(w/w)藜芦酸、1-5%(w/w)梓苷、0.5-5%(w/w)胡黄连苷II、0.5-5%(w/w)异香草酰梓醇和1-5%(w/w)6-O-藜芦酰梓醇;
或者其特征在于,在东北婆婆纳的总提取物(100%)中含有12.3-47%(w/w)梓苷衍生物,且各种梓苷衍生物的重量之间具有如下的相对混合比(w/w):15.0-18.0(w/w)毛蕊花甙、2.10-2.60(w/w)梓苷、1(w/w)胡黄连苷II、1.00-1.30(w/w)异香草酰梓醇以及2.00-2.30(w/w)6-O-藜芦酰梓醇;优选地,16.0-17.0(w/w)毛蕊花甙、2.20-2.50(w/w)梓苷、1(w/w)胡黄连苷II、1.10-1.20(w/w)异香草酰梓醇以及2.10-2.20(w/w)6-O-藜芦酰梓醇;更优选地,16.20-16.99(w/w)毛蕊花甙、2.40-2.45(w/w)梓苷、1(w/w)胡黄连苷II、1.10-1.19(w/w)异香草酰梓醇、2.10-2.19(w/w)6-O-藜芦酰梓醇。
更具体地,术语“用丁醇分馏的纯化提取物(ATC1)”的特征在于,通过如下方法制备:在第一步中,向干燥的东北婆婆纳中加入选自水、C1-C4低级醇(例如甲醇、乙醇、丁醇等)或它们的混合物的至少一种提取溶剂,优选水和乙醇的混合物,更优选30-80(w/w)乙醇的水溶液;在第二步中,在10至100℃、优选20至90℃的温度范围内进行选自热水回流提取、冷水提取、超声波处理或常规提取中的至少一种提取方法30分钟至72小时、优选6至48小时的时间,优选冷水提取后,接着回流提取,更优选地,在10至60℃、优选20至50℃的温度范围内进行冷水提取30分钟至72小时、优选6至48小时的时间,然后在40至120℃、优选60至90℃的温度范围内进行回流提取30分钟至72小时、优选6至48小时的时间,反复进行,以获得第一提取物;在第三步中,将所述第一提取物悬浮在约0.5-10倍体积(v/v)、优选约1-5倍体积(v/v)的水中,以得到悬浮提取物;以及加入约0.5-20倍体积(v/v)、优选约1-10倍体积(v/v)的丁醇,分馏为水层和丁醇层并收集丁醇层以得到用丁醇分馏的纯化提取物(ATC1),以治疗和预防炎性、过敏性或哮喘性疾病,基于东北婆婆纳的总提取物的重量(100%),所述用丁醇分馏的纯化提取物含有15-50%(w/w)毛蕊花甙、0.3-10%(w/w)藜芦酸、0.5-10%(w/w)梓苷、0.3-10%(w/w)胡黄连苷II、0.3-10%(w/w)异香草酰梓醇和0.3-10%(w/w)6-O-藜芦酰梓醇。
因此,在本发明的另一个实施方式中,本发明还提供了用于制备从东北婆婆纳中分离出的用丁醇分馏的纯化提取物(ATC1)的方法,包括以下步骤:在第一步中,向干燥的东北婆婆纳中加入选自水、C1-C4低级醇(例如甲醇、乙醇、丁醇等)或它们的混合物的至少一种提取溶剂,优选水和乙醇的混合物,更优选30-80(w/w)乙醇的水溶液;在第二步中,在10至100℃、优选20至90℃的温度范围内进行选自热水回流提取、冷水提取、超声波处理或常规提取中的至少一种提取方法30分钟至72小时,优选6至48小时的时间,优选冷水提取后接着回流提取,更优选地,在10至60℃、优选20至50℃的温度范围内进行冷水提取30分钟至72小时、优选6至48小时的时间,然后在40至120℃、优选60至90℃的温度范围内进行回流提取30分钟至72小时、优选6至48小时的时间,反复进行,以获得第一提取物;在第三步中,将所述第一提取物悬浮在约0.5-10倍体积(v/v)、优选约1-5倍体积(v/v)的水中,以得到悬浮提取物;以及加入约0.5-20倍体积(v/v)、优选约1-10倍体积(v/v)的丁醇,分馏为水层和丁醇层并收集丁醇层以得到用丁醇分馏的纯化提取物(ATC1),以治疗和预防炎性、过敏性或哮喘性疾病,基于东北婆婆纳的总提取物的重量(100%),所述用丁醇分馏的纯化提取物含有15-50%(w/w)毛蕊花甙、0.3-10%(w/w)藜芦酸、0.5-10%(w/w)梓苷、0.3-10%(w/w)胡黄连苷II、0.3-10%(w/w)异香草酰梓醇和0.3-10%(w/w)6-O-藜芦酰梓醇。
具体地,术语“二级分馏的纯化提取物(ATC2)”的特征在于,基于东北婆婆纳的总提取物的重量(100%),含有30-60%(w/w)毛蕊花甙、0.5-10%(w/w)藜芦酸、2-20%(w/w)梓苷、1-10%(w/w)胡黄连苷II、1-10%(w/w)异香草酰梓醇和2-20%(w/w)6-O-藜芦酰梓醇;优选地,基于东北婆婆纳的总提取物的重量(100%),含有40-50%(w/w)毛蕊花甙、1-5%(w/w)藜芦酸、3-10%(w/w)梓苷、2-5%(w/w)胡黄连苷II、2-8%(w/w)异香草酰梓醇和3-8%(w/w)6-O-藜芦酰梓醇;
或者其特征在于,在东北婆婆纳的总提取物(100%)中含有36.5-91%(w/w)梓苷衍生物,且各种梓苷衍生物的重量之间具有如下的相对混合比(w/w):13.0-16.0(w/w)毛蕊花甙、2.20-2.50(w/w)梓苷、1(w/w)胡黄连苷II、1.10-1.40(w/w)异香草酰梓醇以及2.00-2.20(w/w)6-O-藜芦酰梓醇;优选地,14.0-15.0(w/w)毛蕊花甙、2.30-2.45(w/w)梓苷、1(w/w)胡黄连苷II、1.20-1.35(w/w)异香草酰梓醇以及2.00-2.10(w/w)6-O-藜芦酰梓醇;更优选地,14.50-14.99(w/w)毛蕊花甙、2.35-2.43(w/w)梓苷、1(w/w)胡黄连苷II、1.25-1.34(w/w)异香草酰梓醇、2.01-2.09(w/w)6-O-藜芦酰梓醇。
更具体地,术语“二级分馏的纯化提取物(ATC2)”的特征在于,通过如下方法制备:在第一步中,向干燥的东北婆婆纳中加入选自水、C1-C4低级醇(例如甲醇、乙醇、丁醇等)或它们的混合物的至少一种提取溶剂,优选水和乙醇的混合物,更优选30-80(w/w)乙醇的水溶液;在第二步中,在10至100℃、优选20至90℃的温度范围内进行选自热水回流提取、冷水提取、超声波处理或常规提取的至少一种提取方法30分钟至72小时、优选6至48小时的时间,优选冷水提取后,接着回流提取,更优选地,在10至60℃、优选20至50℃的温度范围内进行冷水提取30分钟至72小时、优选6至48小时的时间,然后在40至120℃、优选60至90℃的温度范围内进行回流提取30分钟至72小时、优选6至48小时的时间,反复进行,以获得第一提取物;在第三步中,将所述第一提取物悬浮在约0.5-10倍体积(v/v)、优选约1-5倍体积(v/v)的水中,以得到悬浮提取物;在第三步中,加入约0.5-20倍体积(v/v)、优选约1-10倍体积(v/v)的丁醇,分馏为水层和丁醇层并收集丁醇层以得到用丁醇分馏的纯化提取物(ATC1);以及对用丁醇分馏的纯化提取物(ATC1)进行选自反相分配色谱、正相分配色谱、离子交换色谱以及尺寸排斥色谱的至少一种纯化工艺以得到二级分馏的纯化提取物(ATC2),以治疗和预防炎性、过敏性或哮喘性疾病,基于东北婆婆纳的总提取物的重量(100%),所述二级分馏的纯化提取物含有30-60%(w/w)毛蕊花甙、0.5-10%(w/w)藜芦酸、2-20%(w/w)梓苷、1-10%(w/w)胡黄连苷II、1-10%(w/w)异香草酰梓醇和2-20%(w/w)6-O-藜芦酰梓醇。
因此,在本发明的另一个实施方式中,本发明还提供用于制备从东北婆婆纳中分离出的二级分馏的纯化提取物(ATC2)的方法,包括以下步骤:在第一步中,向干燥的东北婆婆纳中加入选自水、C1-C4低级醇(例如甲醇、乙醇、丁醇等)或它们的混合物的至少一种提取溶剂,优选水和乙醇的混合物,更优选30-80(w/w)乙醇的水溶液;在第二步中,进行在10至100℃、优选20至90℃的温度范围内选自热水回流提取、冷水提取、超声波处理或常规提取的至少一种提取方法30分钟至72小时、优选6至48小时的时间,优选冷水提取后,接着回流提取,更优选地,在10至60℃、优选20至50℃的温度范围内进行冷水提取30分钟至72小时、优选6至48小时的时间,然后在40至120℃、优选60至90℃的温度范围内进行回流提取30分钟至72小时、优选6至48小时的时间,反复进行,以获得第一提取物;在第三步中,将所述第一提取物悬浮在约0.5-10倍体积(v/v)、优选约1-5倍体积(v/v)的水中,以得到悬浮提取物;在第三步中,加入约0.5-20倍体积(v/v)、优选约1-10倍体积(v/v)的丁醇,分馏为水层和丁醇层并收集丁醇层以得到用丁醇分馏的纯化提取物(ATC1);以及对用丁醇分馏的纯化提取物(ATC1)进行选自反相分配色谱、正相分配色谱、离子交换色谱以及尺寸排斥色谱中的至少一种进一步纯化工艺以得到二级分馏的纯化提取物(ATC2),以治疗和预防炎性、过敏性或哮喘性疾病,基于东北婆婆纳的总提取物的重量(100%),所述二级分馏的纯化提取物含有30-60%(w/w)毛蕊花甙、0.5-10%(w/w)藜芦酸、2-20%(w/w)梓苷、1-10%(w/w)胡黄连苷II、1-10%(w/w)异香草酰梓醇和2-20%(w/w)6-O-藜芦酰梓醇。
具体地,术语“进一步纯化工艺”选自(i)反相分配色谱、(ii)正相分配色谱、(iii)离子交换色谱或(iv)尺寸排斥色谱,优选反相分配色谱或者使用能够在洗脱极性物质的同时保留非极性物质的任何树脂作为固定相的任何色谱,例如葡聚糖凝胶树脂(Sephadexresin),例如葡聚糖凝胶(Sephadex),葡聚糖凝胶LH20(Sephadex LH20),葡聚糖凝胶G-25(Sephadex LH20),葡聚糖凝胶G-10(Sephadex LH20),琼脂糖凝胶(Sepharose),Superdex,甲基丙烯酸酯树脂,羧甲基纤维素,磺丙基纤维素,羧甲基葡聚糖凝胶,磺丙基葡聚糖凝胶,羧甲基琼脂糖凝胶,磺丙基琼脂糖凝胶等;使用苯乙烯-二乙烯基苯共聚物(例如聚合物X、HP20、PRP-h1聚合物等)或甲基丙烯酸酯载体树脂等的反向聚合物树脂;正相硅胶,例如BPC(键合相色谱)产品、从YMC有限公司获得的二氧化硅产品、从DAISO有限公司获得的二氧化硅产品、从ASAHI有限公司获得的二氧化硅产品、从COSMOSYL有限公司获得的二氧化硅产品,等;用于HPLC填料的ODS产品,例如从YMC有限公司获得的ODS产品、从DAISO有限公司获得的ODS产品、从ASAHI有限公司获得的ODS产品、从CHEMCO有限公司获得的ODS产品、从Merck有限公司获得的ODS产品、从COSMOSYL有限公司获得的ODS产品、从FUJI有限公司获得的ODS产品等。
在采用(i)反相分配色谱作为本发明的进一步纯化工艺的优选的实施方式中,“在上述反相分配色谱中的固定相”可以是例如可以在洗脱极性物质的同时保留非极性物质的反相物质作为固定相的任何固定相,优选基于硅胶的固定相,基于聚合物的固定相(例如聚苯乙烯等)等,更优选地,硅胶衍生物,例如C2、C4、C6、C8、C10、C12、14、C16、C18等;或基于聚合物的固定相,例如PS-2、Oasis HLB等,更加优选地,反相硅胶(C18(Ⅳ)-D)、来自YMC有限公司的ODS-A/ODS-AQ产品、来自CHEMCO有限公司的SP-C-ODS产品、来自DAISO有限公司的SP-ODS-RPS产品、来自COSMOSYL有限公司的5C18产品、来自FUJI有限公司的Chromatorex产品等。
在采用(i)反相分配色谱作为本发明的进一步纯化工艺的优选的实施方式中,“在上述(i)反相分配色谱中的流动相”可以是选自水、乙腈、低级醇(例如甲醇、乙醇、丁醇等)、四氢呋喃(THF)或它们的混合物的至少一种溶剂;优选是选自水、低级醇(例如甲醇、乙醇、丁醇等)或它们的混合物的至少一种溶剂;更优选水和甲醇的混合溶剂;更加优选,从90:10(v/v)至60:40(v/v)的水和甲醇的混合物溶剂,以洗脱极性物质。
在采用(ii)正相分配色谱作为本发明的进一步纯化工艺的优选的实施方式中,“在上述正相分配色谱中的固定相”可以是例如可以在洗脱非极性物质的同时保留极性物质的正相物质作为固定相的任何固定相;优选基于硅胶、基于Fluorosyl或基于氧化铝的固定相,基于CN,基于二醇(Diol),或基于NH2部分的聚合物的固定相等;更优选基于硅胶、基于Fluorosyl或基于氧化铝的固定相等。
在采用(ii)正相分配色谱作为本发明的进一步纯化工艺的优选的实施方式中,“在上述(ii)正相分配色谱中的流动相”可以是选自己烷、庚烷、乙酸乙酯、乙醇、乙醚、2-丙醇或它们的混合物的至少一种溶剂,优选是选自己烷、庚烷、乙酸乙酯或它们的混合物的至少一种溶剂,以洗脱非极性物质。
在采用(iii)离子交换色谱作为本发明的进一步纯化工艺的优选的实施方式中,“在上述(iii)离子交换色谱中的固定相”可以是作为具有带电的交联部分的固定相的任何高分子固定相,优选阳离子交换树脂、阴离子交换树脂或合成的吸附剂等,更优选强酸性阳离子交换树脂,例如AG 50W-X8、Amberlite IR-120、Dowex 60W-x8,SKIB等;弱酸性阳离子交换树脂,例如Amberlite IRA-67、Dowex 3-x4A等;强碱性阳离子交换树脂,例如DIAION SKIB、DIAION PK216、DIAION CR20、DIAION UBK555(Mitsubishi Chemical公司)、TRILITE SPC 160H、TRILITE SPC 180H、TRILITE SPC 400JH(Samyang有限公司)、AMBERLITE 200C Na、AMBERLITE CG50、AMBERLITE CR1310Na、AMBERJET200H、AMBERLYST 131WET、ALBERLYST 232WET(ROHM和HAAS有限公司))、Lewatit VP OC 1800、Lewatit VP OC 1812、Lewatit MDS1368Na、Lewaitit K1221(Bayer有限公司)、PUROLITE PCR833CA、PUROLITE C145(Purolite有限公司)、MFG210、MFG250(Finex有限公司)等;强碱性阴离子交换树脂,例如SA11A、SA20A、SA21A等;或者CaptoQ(GE Healthcare有限公司)或具有与其类似性质的树脂,例如Toyopearl QEA(Tosoh有限公司)、Q Sepharose FF(GE Healthcare有限公司)、Fractogel EMD、FractogelTMAE、Fractogel HICAP(Merck KGaA有限公司或Darmstadt有限公司);更优选SA21A;吸附剂,例如SP207、HP20SS、HP20等,更优选HP20。
在采用(iv)尺寸排斥色谱作为本发明的进一步纯化工艺的优选的实施方式中,“在上述(iv)尺寸排斥色谱中的固定相”可以是作为能够通过样品尺寸分离的固定相的任何凝胶型固定相,优选基于葡聚糖的凝胶,例如葡聚糖凝胶(例如葡聚糖凝胶G-25);基于聚丙烯酰胺的凝胶,例如Sephacryl(例如Sephacryl-S400);基于琼脂糖的凝胶,例如Superose或琼脂糖凝胶(Sepharose)(例如琼脂糖凝胶CL-4B)或它们的组合,例如Superdex200组合葡聚糖(例如SephadexTM),或交联的琼脂糖凝胶(SuperoseTM)等,但其不限于此。“在上述(iv)尺寸排斥色谱中的流动相”可以是选自以下的缓冲液:乙酸钠缓冲液、磷酸钠缓冲液、乙酸铵缓冲液、MES(2-(N-吗啉基)乙磺酸)、二-三[2-二(2-羟乙基)氨基-2-(羟甲基)-1,3-丙二醇]、ADA[N-(2-乙酰胺基)亚氨基二乙酸盐)、PIPES[哌嗪-N,N'-二(2-乙磺酸)]、BES[N.N'-二(2-羟乙基)-2-氨基乙磺酸)、MOPS[3-(N-吗啉基)丙磺酸)]、TES(N-三(羟甲基)甲基-2-氨基乙磺酸]、HEPES[N-2-羟乙基-哌嗪-N'-2-乙磺酸)等;优选乙酸钠缓冲液、磷酸钠缓冲液或乙酸铵缓冲液。
在本发明的一个优选实施方式中,作为本文中所公开的进一步纯化工艺,除了(i)反相分配色谱法、(ii)正相分配色谱、(iii)离子交换色谱、(iv)尺寸排斥色谱或它们的组合之外,本发明还可以进行(v)凝胶渗透色谱或凝胶过滤色谱。
本发明还提供由上述制备方法制备的新的纯化提取物,例如(a)用丁醇分馏的纯化提取物(下文中称为“ATC1”)或(b)二级分馏的纯化提取物(下文中称为“ATC2”)。
本发明还提供由上述制备方法制备的用丁醇从东北婆婆纳的提取物分馏的新的纯化提取物(ATC1),其在东北婆婆纳的总提取物(100%)中含有12.3-47%(w/w)梓苷衍生物,其中,基于东北婆婆纳的总提取物的重量(100%),所述梓苷衍生物由15-50%(w/w)毛蕊花甙、0.3-10%(w/w)藜芦酸、0.5-10%(w/w)梓苷、0.3-10%(w/w)胡黄连苷II、0.3-10%(w/w)异香草酰梓醇和0.3-10%(w/w)6-O-藜芦酰梓醇组成;优选地,由20-25%(w/w)毛蕊花甙、0.5-5%(w/w)藜芦酸、1-5%(w/w)梓苷、0.5-5%(w/w)胡黄连苷II、0.5-5%(w/w)异香草酰梓醇和1-5%(w/w)6-O-藜芦酰梓醇组成。
本发明还提供由上述制备方法制备的用丁醇从东北婆婆纳的提取物分馏的新的纯化提取物(ATC1),其显示了各种梓苷衍生物的重量之间的如下的相对混合比(w/w):15.0-18.0(w/w)毛蕊花甙、2.10-2.60(w/w)梓苷、1(w/w)胡黄连苷II、1.00-1.30(w/w)异香草酰梓醇以及2.00-2.30(w/w)6-O-藜芦酰梓醇;优选地,16.0-17.0(w/w)毛蕊花甙、2.20-2.50(w/w)梓苷、1(w/w)胡黄连苷II、1.10-1.20(w/w)异香草酰梓醇以及2.10-2.20(w/w)6-O-藜芦酰梓醇;更优选地,16.20-16.99(w/w)毛蕊花甙、2.40-2.45(w/w)梓苷、1(w/w)胡黄连苷II、1.10-1.19(w/w)异香草酰梓醇、2.10-2.19(w/w)6-O-藜芦酰梓醇。
本发明还提供由上述制备方法制备的从东北婆婆纳的提取物二级分馏的纯化提取物(ATC2),其在东北婆婆纳的总提取物(100%)中含有36.5-91%(w/w)梓苷衍生物,其中,基于东北婆婆纳的总提取物的重量(100%),所述梓苷衍生物由30-60%(w/w)毛蕊花甙、0.5-10%(w/w)藜芦酸、2-20%(w/w)梓苷、1-10%(w/w)胡黄连苷II、1-10%(w/w)异香草酰梓醇和2-20%(w/w)6-O-藜芦酰梓醇组成;优选地,由40-50%(w/w)毛蕊花甙、1-5%(w/w)藜芦酸、3-10%(w/w)梓苷、2-5%(w/w)胡黄连苷II、2-8%(w/w)异香草酰梓醇和3-8%(w/w)6-O-藜芦酰梓醇组成。
本发明还提供由上述制备方法制备的从东北婆婆纳的提取物二级分馏的纯化提取物(ATC2),其显示了各种梓苷衍生物的重量之间的如下的相对混合比(w/w):13.0-16.0(w/w)毛蕊花甙、2.20-2.50(w/w)梓苷、1(w/w)胡黄连苷II、1.10-1.40(w/w)异香草酰梓醇以及2.00-2.20(w/w)6-O-藜芦酰梓醇;优选地,14.0-15.0(w/w)毛蕊花甙、2.30-2.45(w/w)梓苷、1(w/w)胡黄连苷II、1.20-1.35(w/w)异香草酰梓醇以及2.00-2.10(w/w)6-O-藜芦酰梓醇;更优选地,14.50-14.99(w/w)毛蕊花甙、2.35-2.43(w/w)梓苷、1(w/w)胡黄连苷II、1.15-1.24(w/w)异香草酰梓醇、2.01-2.09(w/w)6-O-藜芦酰梓醇。
在本文中公开的术语“纯化提取物”可以以通过真空蒸发法、冷冻干燥法或热空气干燥法等制备的干燥形式使用。
在本文中公开的术语“炎性疾病”包括湿疹、特应性皮炎、结膜炎、牙周病、鼻炎、中耳炎、咽喉炎、扁桃体炎、肺炎、胃溃疡、胃炎、克罗恩病、结肠炎、痔、痛风、强直性脊柱炎、风湿热、系统性红斑狼疮、纤维肌痛、银屑病性关节炎、骨关节炎、风湿性关节炎、肩关节周炎、肌腱炎、腱鞘炎、腱鞘周炎、肌炎、肝炎、膀胱炎、肾炎、干燥综合征(Sjogren’s syndrome)、多发性硬化、慢性炎性疾病、急性炎性疾病等,但本发明并不限于此,优选湿疹、特应性皮炎、风湿性关节炎、慢性炎性疾病、急性炎性疾病等。
在本文中公开的术语“过敏性疾病”包括过敏性鼻炎、过敏性皮炎、接触性皮炎、荨麻疹、昆虫过敏、食物过敏、药物过敏、过敏性结膜炎、超敏反应等,但本发明并不限于此,优选过敏性鼻炎、过敏性皮炎、接触性皮炎、荨麻疹、昆虫过敏、食物过敏、药物过敏,更优选过敏性皮炎、接触性皮炎。
在本文中公开的术语“哮喘性疾病”包括由各种外部因素引起的任何哮喘,例如尘螨、动物的皮毛或皮屑、蟑螂、食物、药物、咳嗽、香烟烟雾、空气污染、食品添加剂、身体活动(例如运动等)、天气变化、黄沙、压力等,但本发明并不限于此。
在本文中公开的术语“预防”包括通过施用本发明组合物以抑制或延迟本文公开的某些疾病或病症的发生的任何行为;以及在本文中公开的术语“治疗”包括通过施用本发明组合物以缓解或有利地改变与本文公开的某些疾病或病症有关的症状的任何行为。
通过各种HPLC分析,本发明人发现,与通过现有技术中公开的常规方法制备的粗提物(其中,梓醇衍生物含量只有8.49%(w/w))相比,用于制备纯化提取物的新的工业化方法可以从东北婆婆纳提供更大量(即36.5%至91.0%(w/w))的活性成分(例如梓醇衍生物),例如,基于东北婆婆纳的总提取物(100%)的重量,本发明的纯化提取物(ATC1)含有17.60%(w/w)毛蕊花甙、0.72%(w/w)藜芦酸、2.62%(w/w)梓苷、1.08%(w/w)胡黄连苷II、1.26%(w/w)异香草酰梓醇和2.36%(w/w)6-O-藜芦酰梓醇(参见实施例2),以及本发明的纯化提取物(ATC2)含有43.83%(w/w)毛蕊花甙、1.80%(w/w)藜芦酸、7.07%(w/w)梓苷、2.93%(w/w)胡黄连苷II、3.85%(w/w)异香草酰梓醇和6.15%(w/w)6-O-藜芦酰梓醇,而由现有技术中公开的常规方法制备的粗提物(CX)只含有5.9%(w/w)毛蕊花甙、0.21%(w/w)藜芦酸、0.82%(w/w)梓苷、0.40%(w/w)胡黄连苷II、0.42%(w/w)异香草酰梓醇和0.74%(w/w)6-O-藜芦酰梓醇;粗提物;以及通过在OVA致敏/激发小鼠模型中各种体内试验(例如对于嗜酸性粒细胞繁殖、血浆和支气管肺泡液中免疫球蛋白和炎症趋化因子的释放的抑制试验以及气道高反应性和杯形细胞增生的抑制),本发明的纯化提取物表现出比通过常规制备方法制备的提取物更有效的抗炎、抗过敏和抗哮喘活性。
因此,根据本发明的另一个方面,本发明提供一种用于炎性、过敏性或哮喘性疾病的治疗和预防的药物组合物,其包含从东北婆婆纳中通过上述方法制备的含有大量活性成分的纯化提取物作为活性成分。
本发明提供一种用于炎性、过敏性或哮喘性疾病的治疗和预防的药物组合物,其包含从东北婆婆纳通过上述方法制备的含有大量活性成分的纯化提取物作为活性成分,和药学上可接受的载体或赋形剂。
根据本发明的另一个方面,还提供从东北婆婆纳通过上述方法制备的含有大量活性成分的纯化提取物用于制备用于治疗或预防炎性、过敏性或哮喘性疾病的药物的用途。
在本文中限定的术语“药学上可接受的载体或赋形剂”包括“药物添加剂,用于构成药物的非活性成分。它们包括染料、香料、粘合剂、软化剂、填料、润滑剂、防腐剂以及更多种类。常规赋形剂包括玉米淀粉、乳糖、滑石、硬脂酸镁、蔗糖、明胶、硬脂酸钙、二氧化硅、虫胶和釉,这是现有技术中已公知的(参见:食品和药物管理局(Food and DrugAdministration)的主页:www.fda.gov或药品信息在线(drug information online):www.drugs.com)或以前的文献(例如,Rowe、Raymond C等人,药用辅料手册(Handbookof Pharmaceutical Excipients),医药出版社(Pharmaceutical Press),第7版,2012)。
根据本发明的另一个方面,还提供在哺乳动物中治疗或预防炎性、过敏性或哮喘性疾病的方法,其中,该方法包括给患有炎性、过敏性或哮喘性疾病的哺乳动物施用治疗有效量的从东北婆婆纳通过上述方法制备的含有大量活性成分的纯化提取物。
基于组合物的总重量,用于治疗和预防炎性、过敏性或哮喘性疾病的本发明组合物可以包含按重量计0.1至99%、优选0.1至50%的上述提取物。
根据本发明的组合物可以提供为药物组合物,所述药物组合物包含药学上可接受的载体、辅料或稀释剂,例如,乳糖、葡萄糖、蔗糖、山梨醇、甘露醇、木糖醇、赤藓醇、麦芽糖醇、淀粉、阿拉伯胶、藻酸盐、明胶、磷酸钙、硅酸钙、纤维素、甲基纤维素、聚乙烯吡咯烷酮、水、羟基苯甲酸甲酯、羟基苯甲酸丙酯、滑石、硬脂酸镁和矿物油。制剂可以另外包括填料、抗凝集剂、润滑剂、润湿剂、调味剂、乳化剂、防腐剂等。本发明的组合物可以通过使用本领域公知的任何方法来配制以在给患者施用后提供活性成分的快速、持续或延迟释放。
例如,本发明的组合物可以溶解在油、丙二醇或者常用于制备注射剂的其他溶剂中。所述载体的合适的实例包括生理盐水、聚乙二醇、乙醇、植物油、肉豆蔻酸异丙酯等,但不限于它们。对于局部给药,本发明的提取物可以配制为软膏和乳膏的形式。
可以以任何形式来制备含有本发明组合物的药物制剂,例如口服剂型(散剂、片剂、胶囊剂、软胶囊剂、含水药物、糖浆剂、酏剂、丸剂、散剂、囊剂、颗粒剂),或局部用制剂(乳膏剂、软膏剂、洗剂、凝胶剂、香膏剂、贴剂、糊剂、喷雾溶液、气雾剂等),或注射制剂(溶液、悬浮液、乳液)。
在药物剂型中的本发明的组合物可以以它们药学上可接受的盐的形式使用,并且也可以单独使用或适当联合使用,以及与其他药学上的活性化合物组合使用。
本发明提取物的理想的剂量根据患者的病情和体重、严重性、药物形式、给药途径和时间而不同,并且可以由本领域技术人员来选择。然而,为了获得理想的效果,通常建议以0.0001至1000mg/kg重量/天的量、优选0.001至100mg/kg重量/天的量施用本发明的发明的提取物。所述剂量可以单次施用或分成每天几次。
本发明的药物组合物可以经由各种途径施用给受试动物(例如哺乳动物(大鼠、小鼠、家畜或人))。考虑了给药的所有模式,例如,给药可以通过口服、经直肠或通过静脉内、肌内、皮下、皮内、鞘内、硬膜外或脑室内注射而进行。
本发明的发明提取物还可以在各种功能性健康食品和保健食品的制备中用作主要成分或添加剂和辅助剂。
因此,本发明的另一目的是提供一种用于预防或缓解炎性、过敏性或哮喘性疾病的健康功能性食品,其包含从东北婆婆纳通过上述方法制备的含有大量活性成分的纯化提取物。
在本文中定义的术语“功能性健康食品”是指通过将本发明的提取物加入到常规食品中以预防或改善人或哺乳动物的目标疾病的“具有增强的功能性(例如物理功能性或生理功能性)的功能性食品。
本发明的另一个目的是提供一种用于预防或缓解炎性、过敏性或哮喘性疾病的保健食品,其包含从东北婆婆纳通过上述方法制备的含有大量活性成分的纯化提取物,以及营养学上可接受添加剂。
在本文中定义的术语“保健食品”是指“以作为添加剂的形式少量或以作为散剂、颗粒、胶囊剂、丸剂、片剂等的形式全部量不显示特定的预期效果但显示一般预期的效果的含有本发明的提取物的食品。
在本文中定义的术语“营养学上可接受的添加剂”包括“预期用途直接或间接地导致或可合理地预期会导致-直接或间接地-其成为一种组分或以其他方式影响任何食物的特性的任何物质”,并且根据其来源可分类为三组,即(1)化学合成的添加剂,例如酮、甘氨酸、柠檬酸钾、烟酸等;(2)天然添加剂,例如柿子染料、甘草提取物、结晶纤维素、瓜达姆(gua dum)等;(3)与此有关的混合添加剂,例如L-谷氨酸钠、防腐剂、焦油染料等,或者根据其在食品中的功能可分类为各种类别,例如增稠剂(thickening agent)、熟化剂、漂白剂、螯合剂、保湿剂、防结块剂、澄清剂、固化剂、乳化剂、稳定剂、稠化剂(thickener)、碱和酸、发泡剂、营养素、着色剂、风味剂、甜味剂、防腐剂、抗氧化剂等,这些是在现有技术或者先前的文献中已公知的(见GSFA Online:www.codexalimentarius.net/gsfaonline/index.html首页页面中的“Codex General Standardfor Food Additives”(GSFA,CODEX STAN 192-1995))。
如果为了在食品中特定目的而将一种物质添加到该食品中,则其被称为直接添加剂,而间接食品添加剂是由于其包装、储存或以其他处理而以痕量成为食品的部分的那些食品添加剂。
为了预防或改善目标疾病,在本文中公开的术语“保健食品或健康功能食品”可以包含在食品、保健饮料、膳食补充剂等中,并且可以配制成药学剂型的形式,例如散剂、颗粒剂、片剂、悬浮液、乳剂、糖浆剂、咀嚼片剂、胶囊剂、饮料等;或食品的形式,例如面包、米糕(rice cake)、干果(dry fruit)、糖果、巧克力、口香糖、冰淇淋、奶(例如低脂奶、水解乳糖奶、山羊奶、加工奶)、乳制品(例如发酵乳、黄油,炼乳、精制奶油、奶油、天然乳酪、加工乳酪、干乳、乳清等)、加工的肉制品(例如汉堡包、火腿、香肠、腊肉等)、加工蛋制品、鱼肉制品(例如鱼饼等)、面条制品(例如方便面、挂面、湿面条、炒面、非油炸面条、糊化干面条、熟面条、冷冻面条、意大利面(Pasta)等)、茶产品(例如袋包茶、过滤茶等)、健康饮料(例如水果饮料、蔬菜饮料、碳酸软饮料、豆奶饮料、乳酸饮料、混合饮料等)、调味食品(例如酱油、豆酱、红辣椒酱、甜面酱(chunjang,一种由焦糖着色的发酵大豆产品)、cheonggukjang(用枯草芽孢杆菌(B.subtillis)天然发酵的大豆)、混合酱、醋、沙司(sauce)、番茄酱、咖喱、调味品(dressing)等)、人造黄油(margarine)、起酥油(shortening)、比萨饼等,但本发明并不限于此。
另外,上述提取物可以添加到食品或饮料中用于预防和改善目标病症。在作为功能性健康食品或保健食品的食品或饮料中的上述提取物的量一般为功能性健康食品组合物的食品的总重量的约0.01至100w/w%。特别是,虽然在功能性健康食品、保健食品或特殊营养食品中的本发明的提取物的优选量可以根据每种食品的预期目的而变化,对于100%的比例的食品组合物,通常优选在食品(例如面条等)中以约0.01至5%的范围、在保健食品中以40至100%的范围的量作为添加剂使用本发明的提取物。
如果本发明的健康饮料组合物以所指示的比率包含上述提取物作为必要成分,对于其他液体组分没有特别的限制,其中所述其它组分可以是各种除臭剂或天然碳水化合物等(例如常规饮料)。上述天然碳水化合物的实例是单糖,例如葡萄糖、果糖等;双糖,例如麦芽糖、蔗糖等;常规糖类,例如糊精、环糊精;以及糖醇,例如木糖醇和赤藓醇等。作为除了上述那些之外的其他除臭剂,天然除臭剂,例如索马甜(taumatin)、甜叶菊提取物(例如levaudioside A)、甘草甜素等;以及合成除臭剂,例如糖精、阿斯巴甜等可以有利地使用。在100ml的本发明饮料组合物的比例中,上述天然碳水化合物的量一般在约1至20g、优选5至12g的范围内。
除了前述组分之外的其它组分是各种营养素、维生素、矿物质或电解质、合成风味剂、在奶酪、巧克力等的情况下的着色剂和改进剂,果胶酸及其盐、海藻酸及其盐、有机酸、保护性胶体粘合剂、pH调节剂、稳定剂、防腐剂、甘油、醇、用于碳酸饮料中的碳化剂等。除了前述成分之外的其它成分可以是用于制备天然果汁、果汁饮料和蔬菜饮料的果汁,其中,所述成分可以单独使用或组合使用。各成分的比例不重要,但通常为每100w/w%本发明组合物中约0至20w/w%。含有上述提取物的可添加的食品的实例为各种食品、饮料、口香糖、维生素复合物、健康改善食品等。
本发明的发明提取物没有毒性,因此没有副作用;它们可以安全使用。
对于本领域技术人员来说,在不脱离本发明的精神或范围内,在本发明的组合物、用途和制备中能够进行各种修改和变型是显而易见的。
通过以下实施例对本发明进行更具体地说明。然而,应该理解的是,本发明并不以任何方式限定于这些实施例。
【有益效果】
如本发明中所述,用于从东北婆婆纳的提取物制备含有更大量的活性成分(例如梓醇衍生物)的纯化提取物的本发明的新的工业化方法,以及通过在OVA致敏/激发小鼠模型中各种体内试验(例如对于嗜酸性粒细胞繁殖、血浆和支气管肺泡液中免疫球蛋白和炎症趋化因子的释放的抑制试验以及气道高反应性和杯形细胞增生的的抑制),显示所述纯化提取物比通过在现有技术中公开的传统制备方法制备的提取物更有效的抗炎、抗过敏和抗哮喘活性。因此,可以用作用于治疗和预防炎性、过敏性或哮喘性疾病的治疗剂或功能性健康食品。
附图说明
结合附图从以下详细描述,可以更清楚地理解本发明的上述和其它目的、特征和其他优点,其中:
图1示出在比较例1中制备的东北婆婆纳的粗提物的HPLC分析;
图2示出实施例1中制备本发明的的东北婆婆纳的纯化提取物(ATC1)的HPLC分析;
图3示出实施例2中制备的本发明的东北婆婆纳的纯化提取物(ATC2)的HPLC分析;
图4示出在OVA致敏/激发小鼠模型中本发明的纯化提取物对气道高反应性的抑制效果;
图5示出本发明的纯化提取物对在支气管肺泡灌洗液中的炎性细胞的聚集的抑制效果;
图6示出本发明的纯化提取物对血清中免疫球蛋白(总IgE)的释放的抑制效果;
图7示出本发明的纯化提取物对血清中OVA特异性IgE的释放的抑制效果;
图8表示本发明的纯化提取物对IL-1β的释放的抑制效果;
图9至11表示本发明的纯化提取物对炎症趋化因子释放的抑制效果;
图12、13表示通过使用支气管肺泡灌洗的组织学检查,本发明的纯化提取物对肺组织细胞中炎性细胞的聚集的抑制效果;
图14、15表示通过使用支气管肺泡灌洗的组织学检查,本发明的纯化提取物对肺组织细胞中粘液分泌的抑制效果。
具体实施方式
对于本领域技术人员来说,在不脱离本发明的精神或范围内,对本发明的组合物、用途和制备进行各种修改和变型是显而易见的。
通过以下实施例对本发明进行更具体地说明。然而,应该理解的是,本发明并不以任何方式限定于这些实施例。
实施例
以下参考实施例、实施例和实验实施例旨在进一步说明本发明而不限制其范围。
比较例1东北婆婆纳的粗提物的制备
1-1粗提物(ATE)的制备
将1kg干东北婆婆纳(按照GAP,在韩国忠清北道阴城郡蘇伊面244号(244,Soi-myeon Eumseong-gun Chungcheongbuk-do)栽培)切成小块,并与10L 40%乙醇混合。将混合物在室温下搅拌24小时,并在78℃下用回流提取进行提取12小时,收集滤液,重复三次。用滤纸过滤提取物以除去碎屑。将收集的滤液在55至65℃下通过旋转蒸发仪(EYELA,N-2100,日本)减压浓缩,并用冷冻干燥机干燥以获得202g干燥粗提物(下文中称为“ACE”),用于作为比较例。
1-2粗提物(ATM)的制备
将1.1kg干东北婆婆纳(按照GAP,在韩国忠清北道阴城郡蘇伊面244号栽培)切成小块,并与5L甲醇混合。将混合物在室温下搅拌24小时,并在78℃用回流提取进行提取12小时,以收集滤液,重复三次。用滤纸过滤提取物以除去碎屑。将收集的滤液在55至65℃下通过旋转蒸发仪(EYELA,N-2100,日本)减压浓缩,并用冷冻干燥机干燥以获得100.5g干燥粗提物(下文中称为“ATM”),用于作为比较例。
1-3成分分析
通过使用HPLC(Agilent 1260型号,USA),根据表1中的条件进行成分分析,其结果示于图1中。
如在图1中所示,已确认,分别在以下时间检测到各个成分:9.548分钟(毛蕊花甙)、10.817分钟(藜芦酸)、16.728分钟(梓苷)、20.346分钟(胡黄连苷II)、21.853分钟(异香草酰梓醇)和30.462分钟(6-O-藜芦酰梓醇)。
根据数学式1,基于HPLC图谱(保留时间),计算样品中每种成分的含量(%)。
[数学式1]
每种成分的含量=标准的浓度(mg/ml)/测试样品的浓度(mg/ml)×At/As×标准的纯度(%)
其中,“At”表示在测试样品中的成分面积,“As”表示在标准中的成分面积,条件是测试样品和标准的采样体积彼此相同。
表1
[表1]
HPLC条件
如在表2中所示,在结果中,已经证实,东北婆婆纳的粗提物仅包含8.49%(w/w)梓苷衍生物,即分别为5.9%(w/w)毛蕊花甙、0.21%(w/w)藜芦酸、0.82%(w/w)梓苷、0.40%(w/w)胡黄连苷II、0.42%(w/w)异香草酰梓醇和0.74%(w/w)6-O-藜芦酰梓醇。
表2
[表2]
HPLC结果(粗提物:ATM)
实施例1东北婆婆纳的纯化提取物(ATC1)的制备
将根据比较例1的常规方法制备的东北婆婆纳的粗提物(ACE)悬浮于2L蒸馏水中,在悬浮液中加入2L丁醇,分馏成可溶于丁醇的馏分和水溶性馏分。收集可溶于丁醇的馏分,减压浓缩并干燥,得到82g本发明的用丁醇分馏的纯化提取物(ATC1)用作实验例。
通过使用HPLC(Agilent 1260型号,USA),根据表1中的条件进行成分分析,其结果示于图2中。
如在图2中所示,已确认,分别在以下时间检测到各个成分:9.545分钟(毛蕊花甙)、10.821分钟(藜芦酸)、16.727分钟(梓苷)、20.345分钟(胡黄连苷II)、21.853分钟(异香草酰梓醇)和30.462分钟(6-O-藜芦酰梓醇)。
根据数学式1,基于HPLC图谱(保留时间),计算样品中每种成分的含量(%)。
如在表3中所示,在结果中,已经证实,东北婆婆纳的本发明的用丁醇分馏的纯化提取物(ATC1)包含25.64%(w/w)梓苷衍生物,即分别为17.60%(w/w)毛蕊花甙、0.72%(w/w)藜芦酸、2.62%(w/w)梓苷、1.08%(w/w)胡黄连苷II、1.26%(w/w)异香草酰梓醇和2.36%(w/w)6-O-藜芦酰梓醇。
表3.
表3
[表3]
HPLC结果(纯化提取物:ATC1)
实施例2东北婆婆纳的纯化提取物(ATC2)的制备
将根据实施例1的东北婆婆纳的本发明的用丁醇分馏的纯化提取物(ATC1)溶解于75ml混合溶剂(蒸馏水:甲醇=1:0.003),并将75g该溶液装载在反相柱色谱(C18(Ⅳ)-D-75-120nm,AGCSi-Tech有限公司,日本,450g),通过使用洗脱溶剂(蒸馏水:甲醇=90:10→60:40)洗脱该悬浮液。收集在初始洗脱溶剂系统(蒸馏水:甲醇=90:10)中运行的8.4L洗脱溶液,并减压浓缩。收集在晚期洗脱溶剂系统(蒸馏水:甲醇=60:40)中运行的5.6L洗脱溶液,减压浓缩并干燥,得到33g本发明的二级分馏的纯化提取物(ATC2)用作实验例。
通过使用HPLC(Agilent 1260型号,USA),根据表1中的条件进行成分分析,其结果示于图3中。
如在图3中所示,已确认,分别在以下时间检测到各个成分:9.525分钟(毛蕊花甙)、10.818分钟(藜芦酸)、16.721分钟(梓苷)、20.346分钟(胡黄连苷II)、21.857分钟(异香草酰梓醇)和30.462分钟(6-O-藜芦酰梓醇)。
根据数学式1,基于HPLC图谱(保留时间),计算样品中每种成分的含量(%)。
如在表4中所示,在结果中,已经证实,东北婆婆纳的本发明的二级分馏的纯化提取物(ATC2)包含65.63%(w/w)梓苷衍生物,即分别为43.83%(w/w)毛蕊花甙、1.80%(w/w)藜芦酸、7.07(w/w)梓苷、2.93%(w/w)胡黄连苷II、3.85%(w/w)异香草酰梓醇和6.15%(w/w)6-O-藜芦酰梓醇。
表4
[表4]
HPLC结果(纯化提取物:ATC2)
实验例1在OVA致敏/激发小鼠模型中总血清IgE水平的初步判定。
为了发现纯化提取物显示出比比较例中制备的粗提物药理学上更有效的活性,通过文献(Elias,J.A.等人,J.Clin.Invest.,111,第297-297页,2003)中公开的方法进行下面的初步试验。
1-1.动物致敏和气道激发
经相关呼吸道病原体常规血清学筛选的无特定病原体的6周龄雌性BALB/c小鼠(约20g),购自ORIENT公司(韩国首尔)并在实验环境驯化1周。
简言之,通过每两周一次腹膜内注射20μg OVA(卵清蛋白;A5503,Sigma,St.Louis,MO)使小鼠致敏,所述OVA在200μl PBS缓冲液(pH 7.4)中的2mg氢氧化铝中乳化。从初次致敏后第28天至34天,使用超声喷雾器(NE-U12;Omron公司,东京,日本)通过气道以OVA(1%,在PBS中)激发小鼠30分钟。抗原处理后24小时,确定气道高反应性并在最后激发后48小时处死小鼠。最后激发后24小时用过量戊巴比妥( Hanrim Pharm.有限公司)处死小鼠,并进行气管切开术。1.2ml生理盐水溶液(PBS)滴入肺后,通过经由气管插管抽吸三次(共1.5ml)获得支气管肺泡灌洗液(BALF)。
分为若干组,即,(a)正常对照组(NC):用OVA处理或不处理的组;(b)哮喘诱发组(OVA):用OVA处理以诱发哮喘的组;以及(c)比较组:吸入OVA之前1小时以阳性对照组(M30,孟鲁司特;30mg/kg,PO,Sigma-Aldrich有限公司,SML-0101)处理的组。
试验组每组由6只小鼠组成,吸入OVA之前1小时,给小鼠口服施用各种浓度的测试样品(ATC1(30mg/kg和100mg/kg)和ATM(30和100mg/kg))。
如表5所示,在哮喘诱发组(OVA)中血清中的IgE的总水平显著增加,而口服施用各种浓度的测试样品(ATC1,330mg/kg和100mg/kg)的测试样品组的血清中的IgE的总水平比用东北婆婆纳的粗提物(ATM,30和100mg/kg)处理的组的血清中的IgE的总水平降低的更多。(见表5)
表5
[表5]
血清中的总IgE水平
实验例2.在OVA致敏/激发小鼠模型中使用气道高反应性测试的抗哮喘效果
为了证实实施例中制备的测试样品在OVA致敏/激发小鼠模型中使用气道高反应性测试的抗哮喘效果,通过文献(Elias,J.A.等人,J.Clin.Invest.,111,第297-297页,2003)中公开的方法进行下面的试验。
1-1.动物致敏和气道激发
经相关气道病原体常规血清学筛选的无特定病原体的6周龄雌性BALB/c小鼠(约20g),购自ORIENT公司(韩国首尔)并在实验环境驯化1周。
简言之,通过每两周一次腹膜内注射20μg OVA(卵清蛋白;A5503,Sigma,St.Louis,MO)使小鼠致敏,所述OVA在200μl PBS缓冲液(pH 7.4)中的2mg氢氧化铝中乳化。初次致敏后从第28天至34天,使用超声喷雾器(NE-U12;Omron公司,东京,日本)通过气道以OVA(1%,在PBS中)激发小鼠30分钟。抗原处理后24小时,确定气道高反应性并在最后激发后48小时处死小鼠。最后激发后24小时用过量戊巴比妥(Entobal,Hanrim Pharm.有限公司)处死小鼠,并进行气管切开术。1.2ml生理盐水溶液(PBS)滴入肺后,通过经由气管插管抽吸三次(总共1.5ml)获得支气管肺泡灌洗液(BALF)。
研究小鼠组(n=6);它们受到以下处理:(1)以OVA的非处理组作为正常对照组(NC);(2)处理并吸入OVA的对照组作为哮喘诱发组(OVA);(3)吸入OVA之前1小时以已知的哮喘治疗剂处理的阳性对照组(孟鲁司特;30mg/kg,PO,韩国Sigma-Aldrich,SML-0101,M30);(4)吸入OVA之前1小时,口服施用不同浓度的测试样品(即,5mg/kg、10mg/kg、25mg/kg和50mg/kg的纯化提取物(ATC2))的测试样品组。
1-2气道高反应性的评价
为了评价小鼠的气道高反应性,通过用仪器(单室全身体积描记系统(One chamberwhole body plethymography),OCP3000,All Medicus,首尔,韩国)测定气道阻力,通过表现气道阻塞程度的Pehn值(增强暂停)来进行统计学计算所侧定的值。通过测定在正常呼吸阶段的基值以及测定用超声雾化器(NE-U12,IMRON公司,东京,日本)吸入PBS 3分钟后的Pehn值的过程,测定Pehn值3分钟。
此后,随着浓度增加吸入各种浓度(12、25和50mg/ml)的乙酰甲胆碱(A2251,Sigma,St.Louis,MO),以测定Pehn值。Pehn值的增加表示为吸入乙酰甲胆碱后的百分比(%),Pehn值的基线设定为100%。Pehn的值根据数学式2计算,结果在图4中示出。
[数学式2]
Pehn=(Te/RT-1)×PEF/PIF
TE:呼气时间(从吸气到下一次吸气的时段);
RT:松弛时间(呼气期间呼出体积达到一次呼气体积的30%的程度的时段)
PEF:呼气流量峰
PIF:吸气流量峰
在结果中,已经证实,随着乙酰甲胆碱的浓度增加,在作为哮喘诱发组(OVA)的处理并吸入OVA的对照组中,Penh值急剧增加,而在作为正常对照组(NC)的OVA的非处理组中,Penh值逐渐增加。
在一段时间,不管乙酰甲胆碱的浓度如何,在以孟鲁司特(MO)处理的阳性对照组中以及以不同浓度(ATC-10、ATC-25和ATC-50)的测试样品口服施用的测试样品组中,Penh值显著降低。(见表6)
表6
[表6]
已经证实,Penh值的这种变化在高剂量乙酰甲胆碱处理组而不是在低剂量乙酰甲胆碱处理组中显著,对于相同浓度的乙酰甲胆碱,测试样品中的Penh值以剂量依赖方式显著地降低。
因此,已经证实,本发明的纯化的提取物有效地抑制气道高反应性,因此,它们可用于治疗或预防气道中的哮喘性疾病、过敏性疾病。
实验例3对于BALF中嗜酸性粒细胞和炎性细胞的水平的影响
为了证实实施例制备的测试样品对于支气管肺泡液(BALF)中嗜酸性粒细胞和炎性细胞的水平的抑制效果,通过文献(Chen M.等人,Immunolgy,第376-384页,2011)中公开的方法进行下面的试验。
回收实验例1中制备的支气管肺泡灌洗液(BALF),以测定炎性细胞的水平。
通过用锥虫蓝(trypan blue)染色排除死细胞后,在血细胞计数器的至少五个正方形中计数细胞以评估总炎性细胞数目(Daigle I.等人,Swiss Med Wkly,131,第2317页,2001)。将100μl BALF加到载玻片上并使用Cellspin机(Cyto12.5+clip5,Hanil Science Industrial,韩国)离心(200×g,4℃,10分钟)以将细胞固定在载玻片上。根据制造商的说明,用染色试剂(Sysmex,Cat No.38721,瑞士)给细胞染色。对独立的平均值通过Student氏双尾t-检验确定统计学显著性,并将显著性的临界水平设定在P<0.05。
如图5中所示,与作为正常对照组(NC)的OVA的非处理组中的嗜酸性粒细胞和炎性细胞的总数目相比,作为哮喘诱发组(OVA)的处理并吸入OVA的对照组中的嗜酸性粒细胞和炎性细胞的总数目显著增加。
在以孟鲁司特(MO)处理的阳性对照组中以及以不同浓度(ATC-5、ATC-10、ATC-25和ATC-50)的测试样品口服施用的测试样品组中,嗜酸性粒细胞和炎性细胞的总数目显著降低。(见表7)
表7
[表7]
BALF中嗜酸性粒细胞和炎性细胞的总数目
实验例4对血清中IgE和OVA特异性IgE的水平的影响
为了证实实施例制备的测试样品对血清中IgE和OVA特异性IgE的水平的抑制效果,通过文献(Kay,A.B.,The New England Journal of Medicine,344,第30-37页,2001)中公开的方法进行下面的试验。
回收实验例1中制备的血清和支气管肺泡灌洗液(BALF),以确定血清中IgE和OVA特异性IgE的水平。
将血清和支气管肺泡灌洗液(BALF)加入到96孔板(ELISA板),并在4℃下用含20μg/ml OVA(Sigma,MO,USA)的0.1M碳酸氢钠缓冲液(pH 8.3)包被过夜。通过使用含有1%牛血清白蛋白的PBS抑制非特异性反应后,将用于测试的血清稀释至1:400,并在室温下共同反应2小时。洗涤后,在室温下,使血清与稀释的(x 300)抗小鼠IgE单克隆抗体(MCA419,Serotec,Oxford,UK)反应2小时,再与稀释的(x4000)结合HRP的山羊抗大鼠IgG多克隆A(STAR110P,Serotec,UK)反应1小时。洗涤后,用3,3',5,5'-四甲基联苯胺(52-00-02,KPL)底物对溶液进行染色,用2N H2SO4停止反应,使用分光光度计(VersaMax,Molecular Devices,US)在450nm处测定吸光度。
如图6和图7所示,作为哮喘诱发组(OVA)的处理并吸入OVA的对照组中的血清中的IgE和OVA特异性IgE水平显著增加,而在以孟鲁司特(MO)处理的阳性对照组中以及以不同浓度(ATC-5、ATC-10、ATC-25和ATC-50)的测试样品口服施用的测试样品组中,血清中的IgE和OVA特异性IgE水平显著降低。(见表8)
表8
[表8]
血清中IgE和OVA特异性IgE的水平
因此,已经证实,本发明的纯化提取物有效地抑制血清中的IgE和OVA特异性IgE的水平,因此,它们可以用于治疗或预防过敏性疾病和哮喘性疾病。
实验例5对BALF中炎性细胞因子的水平的影响
为了证实实施例中制备的测试样品对于支气管肺泡灌洗液(BALF)中Th2细胞因子(IL-4、IL-5和IL-13)和IL-1β的水平的抑制效果,通过在文献(Renz H.等人,J.Exp.Med.,1777,第1175-1180页,1993)中公开的夹心酶免疫吸附测定法(sandwich enzymeimmunosorbent assay method)进行以下试验。
在室温下将血清和支气管肺泡灌洗液(BALF)加入到以细胞因子抗体包被的96孔板(ELISA板)以诱导抗原抗体反应进行2小时。根据制造商的说明书,使用与每种细胞因子特异性反应的ELISA试剂盒(Biosource Int.CA,USA)测定支气管肺泡灌洗液(BALF)中的Th2细胞因子(IL-4,IL-5和IL-13)和IL-1β的水平。
如图8和图9-11中所示,OVA处理后48小时,与作为正常对照组(NC)的OVA的非处理组中的Th2细胞因子(IL-4,IL-5和IL-13)和IL-1β水平相比,作为哮喘诱发组(OVA)的处理并吸入OVA的对照组中Th2细胞因子(IL-4,IL-5和IL-13)和IL-1β的水平显著增加。
在以孟鲁司特(MO,30mg/kg)处理的阳性对照组中以及以不同浓度(ATC-10、ATC-25和ATC-50)的测试样品口服施用的测试样品组中Th2细胞因子(IL-4,IL-5和IL-13)和IL-1β的增加水平显著降低。(见表9)
表9
[表9]
Th2细胞因子(IL-4,IL-5和IL-13)和IL-1β的水平
因此,已经证实,本发明的纯化提取物有效地抑制BALF中Th2细胞因子(IL-4、IL-5和IL-13)和IL-1β的水平,因此,它们可用于治疗或预防过敏性疾病和哮喘性疾病。
实验例6肺组织学
为了证实实施例中制备的测试样品的抗哮喘效果,通过在文献(Kwak YG.等人,J.Clin.Invest.,111,第1083-1092页,2003)中所公开的方法进行以下对支气管肺泡组织的组织病理学分析。
将没有进行支气管肺泡灌洗的BALB/c小鼠的交付(delivered)肺组织固定于10%中性缓冲的福尔马林中24小时。包埋在石蜡中之后,然后制成4-厚切片,用H&E溶液(苏木精;Sigma MHS-16和曙红,Sigma HT110-I-32)将组织染色,测定以随机的方式选择的每个切片中的五个区域中的炎症评分(炎症评分0:支气管周围没有发现发炎细胞,炎症评分1:支气管周围零星地发现发炎细胞,炎症评分2:在大多数支气管周围发现薄发炎细胞层,炎症评分3:在大多数支气管周围发现厚发炎细胞层)。
如图12、13中所示,在作为哮喘诱发组(OVA)的处理并吸入OVA的对照组中,在细支气管周围发现许多包括嗜酸性粒细胞的炎性细胞,并且也发现了上皮细胞的增生以及气管肌的肥大,而在以孟鲁司特(MO,30mg/kg)处理的阳性对照组中以及以不同浓度(ATC-10、ATC-25和ATC-50)的测试样品口服施用的测试样品组中发炎细胞的入侵显著减少。(见表10)
表10
[表10]
细支气管上皮细胞中的炎性评分和杯形细胞的比例
实验例7杯形细胞生长的评估
为了证实实施例中制备的测试样品的抗哮喘效果,通过在文献(Lee KS.等人,FASEBJ.,20,第455-465页,2006)中所公开的方法进行以下对支气管肺泡组织的杯形细胞生长分析。
将没有进行支气管肺泡灌洗的BALB/c小鼠的交付肺组织固定于10%中性缓冲的福尔马林中24小时。包埋在石蜡中之后,然后制成4-厚切片,用高碘酸-希夫(PAS染色试剂盒,T-K7308,IMEB,CA,USA)将组织染色,以测定在细支气管上皮细胞中杯形细胞的比率。
如图14、15所示,与正常对照组(Nc)相比,在作为哮喘诱发组(OVA)的处理并吸入OVA的对照组中的细支气管上皮细胞中的杯形细胞的比率显著增加,而在以孟鲁司特(MO,30mg/kg)处理的阳性对照组中以及以不同浓度(ATC-10、ATC-25和ATC-50)的测试样品口服施用的测试样品组中在细支气管上皮细胞中杯形细胞的比率显著减少。(见表9)
实验例8在大鼠中口服给药的急性毒性试验
通过给6周龄的SPF Sprague-Dawley大鼠施用本发明提取物以进行急性毒性试验。
给每组由2只大鼠组成的各组口服施用250mg/kg、500mg/kg、1000mg/kg、5000mg/kg的本发明的提取物,观察大鼠的症状进行14天。施用该提取物后,观察所有的临床变化(即死亡率、临床症状、体重变化),并进行血液检测(例如血液病学检测和血液生化检测)。尸体解剖后观察腹腔脏器和胸部器官的异常变化。
在任何组或任一性别中没有显示出死亡率、临床症状、体重变化和总体结果上的任何变化。此外,以5000mg/kg的本发明提取物处理的试验组中表现出一些毒性。
因此,已经证实的是,本发明中制备的发明提取物为在口服给药中显示LD50(超过5000mg/kg)的有效且安全的物质。
【发明方式】
在下文中,将对配制方法和赋形剂的种类进行说明,但本发明并不限定于此。代表性的制备实施例描述如下。
注射剂的制备
ATC1提取物…………………….100mg
焦亚硫酸钠………………………3.0mg
对羟基苯甲酸甲酯……………0.8mg
对羟基苯甲酸丙酯……………0.1mg
注射用蒸馏水…………………适量
注射制剂是通过常规注射制备方法通过溶解活性组分,控制pH至约7.5,然后将所有组分装入2ml的安瓿瓶中并灭菌。
散剂的制备
ATC2提取物……………………500mg
玉米淀粉………………………100mg
乳糖………………………100mg
滑石………………………10mg
散剂是通过混合上述成分并填充密封的包装而制备。
片剂的制备
ATC1提取物………………………200mg
玉米淀粉………………………100mg
乳糖………………………100mg
硬脂酸镁…………………适量
片剂通过混合上述成分并压片而制备。
胶囊的制备
ATC2提取物………………………100mg
乳糖………………………50mg
玉米淀粉………………………50mg
滑石………………………2mg
硬脂酸镁………………………适量
片剂制剂是通过常规明胶制备方法通过混合上述成分并填充于明胶胶囊中制备。
液体的制备
ATC1提取物………………………1000mg
糖……………………………20g
多糖…………………………20g
柠檬香料………………………20g
液体制剂是通过常规液体制备方法通过将活性成分溶解,然后将所有成分填充在000ml安瓿瓶中并灭菌而制备。
健康食品的制备
ATC2提取物………………………1000mg
维生素混合物………………………适量
维生素A醋酸酯……………………70g
维生素E………………………1.0mg
维生素B1………………………0.13mg
维生素B2………………………0.15mg
维生素B6………………………0.5mg
维生素B12………………………0.2g
维生素C………………………10mg
生物素………………………10g
酰胺烟酸………………………1.7mg
叶酸………………………50g
钙泛酸………………………0.5mg
矿物质混合物………………………适量
硫酸亚铁………………………1.75mg
氧化锌………………………0.82mg
碳酸镁………………………25.3mg
磷酸二氢钾………………………15mg
磷酸二钙………………………55mg
柠檬酸钾………………………90mg
碳酸钙………………………100mg
氯化镁………………………24.8mg
上述维生素和矿物质混合物可以以多种方式进行改变。这样的变化不应被视为背离本发明的精神和范围。
健康饮料的制备
ATC1提取物………………………1000mg
柠檬酸………………………1000mg
寡糖………………………100g
杏浓缩物………………………2g
牛磺酸………………………1g
蒸馏水………………………900ml
健康饮料的制备是通过常规的健康饮料制备方法通过将活性组分溶解,混合、在85℃搅拌1小时,过滤,然后将所有成分填充入1000ml安瓿瓶并灭菌而制备。
尽管如此描述本发明,但很明显的是可以在许多方面进行改变。这些变化不应被视为背离本发明的精神和范围,并且对于本领域技术人员来讲将是显而易见的所有这样的修改都旨在包括在以下权利要求的范围之内。
【工业实用性】
如本发明中所述,本发明提供用于从东北婆婆纳的提取物制备含有更大量的活性成分(例如梓醇衍生物)的纯化提取物的本发明的新的工业化方法,并且通过在OVA致敏/激发小鼠模型中各种体内试验(例如对于嗜酸性粒细胞(eosinolphil)繁殖、血浆和支气管肺泡液中免疫球蛋白和炎症趋化因子的释放的抑制试验以及气道高反应性和杯形细胞增生的抑制),所述纯化提取物表现出比通过在现有技术中公开的传统制备方法制备的提取物更有效的抗炎、抗过敏和抗哮喘活性。因此,其可以用作用于治疗和预防炎性、过敏性或哮喘性疾病的治疗剂或功能性健康食品。
Claims (4)
1.一种从东北婆婆纳的提取物用丁醇分馏的纯化提取物(ATC1),通过如下方法制备:在第一步中,向干燥的东北婆婆纳中加入30-80%乙醇,并在20至50℃的温度范围内进行冷水提取6至48小时的时间;然后在60至90℃的温度范围内用热水进行回流提取6至48小时的时间,进行2至10次以获得第一提取物;将所述第一提取物悬浮在1-5倍体积(v/v)的水中,加入1-10倍体积(v/v)的丁醇,分馏为水层和丁醇层并收集丁醇层以得到用丁醇分馏的纯化提取物(ATC1),基于东北婆婆纳的总提取物的重量(100%),所述用丁醇分馏的纯化提取物(ATC1)含有15-50%(w/w)毛蕊花甙、0.3-10%(w/w)藜芦酸、0.5-10%(w/w)梓苷、0.3-10%(w/w)胡黄连苷II、0.3-10%(w/w)异香草酰梓醇和0.3-10%(w/w)6-O-藜芦酰梓醇。
2.一种从东北婆婆纳的提取物用丁醇分馏的纯化提取物(ATC1),通过如下方法制备:在第一步中,向干燥的东北婆婆纳中加入30-80%的乙醇,并在20至50℃的温度范围内进行冷水提取6至48小时的时间;然后在60至90℃的温度范围内用热水进行回流提取6至48小时的时间,进行2至10次以获得第一提取物;将所述第一提取物悬浮在约1-5倍体积(v/v)的水中,加入约1-10倍体积(v/v)的丁醇,分馏为水层和丁醇层并收集丁醇层以得到用丁醇分馏的纯化提取物(ATC1),所述用丁醇分馏的纯化提取物(ATC1)在东北婆婆纳的总提取物(100%)中含有12.3-47%(w/w)梓醇衍生物,且显示各种梓醇衍生物的重量之间如下的相对混合比(w/w):15.0-18.0(w/w)毛蕊花甙、2.10-2.60(w/w)梓苷、1(w/w)胡黄连苷II、1.00-1.30(w/w)异香草酰梓醇以及2.00-2.30(w/w)6-O-藜芦酰梓醇。
3.一种用于治疗和预防炎性、过敏性或哮喘性疾病的药物组合物,其包含:
作为活性成分的从东北婆婆纳中分离的权利要求1或2所述的用丁醇分馏的纯化提取物(ATC1),以及药学上可接受的载体或赋形剂,所述炎性、过敏性或哮喘性疾病选自湿疹,特应性皮炎,风湿性关节炎,慢性炎性疾病,急性炎性疾病,过敏性皮炎,接触性皮炎,由尘螨、食物、药物、咳嗽、香烟烟雾、空气污染、食品添加剂、天气变化或黄沙引起的哮喘。
4.一种用于预防或缓解炎性、过敏性或哮喘性疾病的健康功能性食品,其包含从东北婆婆纳分离的权利要求1或2所述的用丁醇分馏的纯化提取物(ATC1),所述炎性、过敏性或哮喘性疾病选自湿疹,特应性皮炎,风湿性关节炎,慢性炎性疾病,急性炎性疾病,过敏性皮炎,接触性皮炎,由尘螨、食物、药物、咳嗽、香烟烟雾、空气污染、食品添加剂、天气变化或黄沙引起的哮喘。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610286764.0A CN105963312B (zh) | 2012-12-31 | 2013-12-23 | 从东北婆婆纳中分离的纯化提取物、其制备方法以及包含该提取物的组合物 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0158130 | 2012-12-31 | ||
KR20120158130 | 2012-12-31 | ||
KR1020130084167A KR101476045B1 (ko) | 2012-12-31 | 2013-07-17 | 활성성분을 다량 함유한 산꼬리풀 정제 분획물 (atc2), 이의 제조방법 및 이를 유효성분으로 포함하는 염증, 알레르기 및 천식의 예방 또는 치료용 조성물 |
KR10-2013-0084167 | 2013-07-17 | ||
PCT/KR2013/011986 WO2014104672A1 (en) | 2012-12-31 | 2013-12-23 | A purified extract isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610286764.0A Division CN105963312B (zh) | 2012-12-31 | 2013-12-23 | 从东北婆婆纳中分离的纯化提取物、其制备方法以及包含该提取物的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104822386A CN104822386A (zh) | 2015-08-05 |
CN104822386B true CN104822386B (zh) | 2016-08-31 |
Family
ID=51736806
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380062681.8A Active CN104822386B (zh) | 2012-12-31 | 2013-12-23 | 从东北婆婆纳中分离的含有大量活性成分的纯化提取物、其制备以及包含该提取物作为活性成分用于预防或治疗炎症、过敏和哮喘的组合物 |
CN201610286764.0A Active CN105963312B (zh) | 2012-12-31 | 2013-12-23 | 从东北婆婆纳中分离的纯化提取物、其制备方法以及包含该提取物的组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610286764.0A Active CN105963312B (zh) | 2012-12-31 | 2013-12-23 | 从东北婆婆纳中分离的纯化提取物、其制备方法以及包含该提取物的组合物 |
Country Status (14)
Country | Link |
---|---|
US (2) | US9592263B2 (zh) |
EP (2) | EP2941263B1 (zh) |
JP (2) | JP5923222B2 (zh) |
KR (2) | KR101476045B1 (zh) |
CN (2) | CN104822386B (zh) |
AU (1) | AU2013371216B2 (zh) |
BR (2) | BR122019025952B1 (zh) |
CA (2) | CA2893410C (zh) |
EC (1) | ECSP15021216A (zh) |
ES (1) | ES2719265T3 (zh) |
MX (1) | MX361137B (zh) |
PL (1) | PL2941263T3 (zh) |
RU (3) | RU2606768C1 (zh) |
WO (1) | WO2014104672A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10046019B2 (en) | 2012-12-31 | 2018-08-14 | Yungjin Pharmaceutical Co., Ltd | Purified extract (ATC1) isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999646B2 (en) | 2012-12-31 | 2018-06-19 | Yungjin Pharmaceutical Co., Ltd | Method of treating inflammation, allergy and asthma with a purified extract (ATC1) isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient |
KR101476095B1 (ko) * | 2013-04-10 | 2014-12-23 | 영진약품공업주식회사 | 고함량의 카탈폴 유도체를 다량 함유한 산꼬리풀 유래 꼬리풀 신규 정제물 또는 이로부터 분리된 카탈폴 유도체를 유효성분으로 포함하는 만성 폐쇄성 폐질환의 예방 또는 치료용 조성물 |
KR101638795B1 (ko) * | 2014-07-24 | 2016-07-12 | 영진약품공업주식회사 | 산꼬리풀 추출물로부터 분리된 신규 화합물 및 이를 유효성분으로 포함하는 알러지, 염증, 천식 또는 만성 폐쇄성 폐질환의 예방 또는 치료용 조성물 |
KR101715676B1 (ko) * | 2015-06-17 | 2017-03-13 | 영진약품공업주식회사 | 산꼬리풀 추출물로부터 분리된 신규 화합물 (ks 513) 및 이를 유효성분으로 포함하는 알러지, 염증, 천식 또는 만성 폐쇄성 폐질환의 예방 또는 치료용 조성물 |
CN106353433B (zh) * | 2016-10-13 | 2018-09-14 | 昆明赛诺制药股份有限公司 | 一种治疗乙型肝炎美洲大蠊提取物的检测方法 |
KR20180060201A (ko) * | 2016-11-28 | 2018-06-07 | 한국과학기술연구원 | 땅콩 지상부 추출물 및 분획물을 포함하는 피부염 치료용 조성물 및 그의 용도 |
GB201705403D0 (en) * | 2017-04-04 | 2017-05-17 | Givaudan Sa | Improvements in or relating to organic compounds |
CN107937340B (zh) * | 2017-11-21 | 2021-06-25 | 大连医科大学附属第一医院 | 梓醇在促进神经干细胞向少突胶质细胞分化中的应用 |
US20220233625A1 (en) * | 2019-05-08 | 2022-07-28 | Kt&G Corporation | Composition for preventing or treating inflammation, allergies and asthma, containing veronicastrum sibiricum l. pennell as active ingredient, and use thereof |
WO2021071375A1 (ru) * | 2019-10-07 | 2021-04-15 | Александр Иванович Леляк | Функциональная питьевая вода |
KR102309959B1 (ko) | 2020-03-16 | 2021-10-08 | 아주대학교 산학협력단 | 진세노사이드 Rg 5를 포함하는 점액 과다 분비 질환의 예방 또는 치료용 조성물 |
CN112774247A (zh) * | 2020-12-09 | 2021-05-11 | 黄永利 | 一种化妆品生产用原料提取设备及化妆品生产方法 |
CN114432330A (zh) * | 2022-03-01 | 2022-05-06 | 贵州大学 | 胡黄连苷ii在制备预防和治疗炎症性肠病药物中的用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100860080B1 (ko) * | 2005-05-30 | 2008-09-24 | 한국생명공학연구원 | 항염, 항알레르기 및 항천식 활성을 갖는 꼬리풀속 식물추출물을 함유하는 약학조성물 |
US8455541B2 (en) * | 2005-05-30 | 2013-06-04 | Korea Research Institute Of Bioscience And Biotechnology | Pharmaceutical composition comprising an extract of pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
KR20060125499A (ko) * | 2005-05-30 | 2006-12-06 | 한국생명공학연구원 | 항염, 항알레르기 및 항천식 활성을 갖는 긴산꼬리풀추출물로부터 분리된 카탈폴 유도체를 함유하는 약학조성물 |
US8168235B2 (en) * | 2005-05-30 | 2012-05-01 | Korea Research Institute Of Bioscience And Biotechnology | Pharmaceutical composition comprising an extract of Pseudolysimachion longifolium and the catalpol derivatives isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity |
KR101313860B1 (ko) | 2012-01-16 | 2013-10-14 | (주)이오시스템 | 광학장치 |
KR101476045B1 (ko) | 2012-12-31 | 2014-12-23 | 영진약품공업주식회사 | 활성성분을 다량 함유한 산꼬리풀 정제 분획물 (atc2), 이의 제조방법 및 이를 유효성분으로 포함하는 염증, 알레르기 및 천식의 예방 또는 치료용 조성물 |
KR20140136790A (ko) | 2013-05-21 | 2014-12-01 | 김현우 | 차량의 주차 완료 후 주차 안전거리를 확보하는 방법 및 장치 |
-
2013
- 2013-07-17 KR KR1020130084167A patent/KR101476045B1/ko active IP Right Review Request
- 2013-12-23 CA CA2893410A patent/CA2893410C/en active Active
- 2013-12-23 AU AU2013371216A patent/AU2013371216B2/en active Active
- 2013-12-23 CA CA2951501A patent/CA2951501C/en active Active
- 2013-12-23 CN CN201380062681.8A patent/CN104822386B/zh active Active
- 2013-12-23 ES ES13869176T patent/ES2719265T3/es active Active
- 2013-12-23 JP JP2015550305A patent/JP5923222B2/ja active Active
- 2013-12-23 WO PCT/KR2013/011986 patent/WO2014104672A1/en active Application Filing
- 2013-12-23 PL PL13869176T patent/PL2941263T3/pl unknown
- 2013-12-23 EP EP13869176.1A patent/EP2941263B1/en active Active
- 2013-12-23 CN CN201610286764.0A patent/CN105963312B/zh active Active
- 2013-12-23 RU RU2015117410A patent/RU2606768C1/ru active
- 2013-12-23 BR BR122019025952-6A patent/BR122019025952B1/pt active IP Right Grant
- 2013-12-23 US US14/653,852 patent/US9592263B2/en active Active
- 2013-12-23 EP EP19154289.3A patent/EP3498287A1/en active Pending
- 2013-12-23 RU RU2016128789A patent/RU2674757C1/ru active
- 2013-12-23 MX MX2015006929A patent/MX361137B/es active IP Right Grant
- 2013-12-23 BR BR112015012568-9A patent/BR112015012568B1/pt active IP Right Grant
-
2014
- 2014-10-10 KR KR1020140136790A patent/KR101504651B1/ko active IP Right Grant
-
2015
- 2015-05-28 EC ECIEPI201521216A patent/ECSP15021216A/es unknown
-
2016
- 2016-02-29 JP JP2016036960A patent/JP6132942B2/ja active Active
- 2016-09-11 US US15/261,998 patent/US10046019B2/en active Active
-
2018
- 2018-03-26 RU RU2018110651A patent/RU2682653C1/ru active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10046019B2 (en) | 2012-12-31 | 2018-08-14 | Yungjin Pharmaceutical Co., Ltd | Purified extract (ATC1) isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104822386B (zh) | 从东北婆婆纳中分离的含有大量活性成分的纯化提取物、其制备以及包含该提取物作为活性成分用于预防或治疗炎症、过敏和哮喘的组合物 | |
KR101128088B1 (ko) | 코로나 바이러스 감염의 예방 또는 치료용 조성물 및 3cl 프로테아제 활성의 억제용 조성물 | |
KR101604347B1 (ko) | 피스타시아 웨인마니폴리아 추출물 또는 이의 분획물을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물 | |
US9999646B2 (en) | Method of treating inflammation, allergy and asthma with a purified extract (ATC1) isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient | |
US20180105548A1 (en) | A novel compound (KS-513) isolated from Pseudolysimachion rotundum var. subintegrum, the composition comprising the same preventing or treating allergic disease, inflammatory disease, asthma or chronic obstructive pulmonary disease and the use thereof | |
KR20110086473A (ko) | 감태 추출물을 포함하는 코로나 바이러스 감염의 예방 또는 치료용 조성물 및 3cl 프로테아제 활성의 억제용 조성물 | |
KR101078365B1 (ko) | 조개풀 추출물 또는 이의 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물 | |
CN106795170B (zh) | 预防或治疗变应性疾病、哮喘等疾病的化合物、组合物及它们的用途 | |
KR101715154B1 (ko) | 회양목 추출물 또는 이의 분획물을 포함하는 천식의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |